


HCV in Pregnancy


Testing

Recommendation for Universal Hepatitis C Screening in Pregnancy	
RECOMMENDED	RATING 
All pregnant women should be tested for HCV infection (see Recommendations for Initial HCV Testing and Follow-Up), ideally at the initiation of prenatal care.	IIb, C


It has been estimated that up to 29,000 HCV-infected women gave birth each year from 2011 to 2014 ([Ly, 2017](#)). With the current increases in HCV among young adults, including women of childbearing age ([Koneru, 2016](#)); ([Kuncio, 2016](#)); ([Watts, 2017](#)), there is now discussion about universal screening of pregnant women ([Prasad, 2016](#)). Risk factor-based testing has never been shown to be effective ([Kuncio, 2015](#)); ([Waruingi, 2015](#)); ([Fernandez, 2016](#)) and inconsistent screening and counseling practices have been reported among obstetricians and gynecologists ([Boaz, 2003](#)). The Society for Maternal-Fetal Medicine recommends several obstetrical practices in women with HCV infection, including preference for amniocentesis over chorionic villus sampling when invasive prenatal diagnostic testing is indicated, as well as avoidance of internal fetal monitoring during labor, prolonged rupture of membranes, and episiotomies ([Hughes, 2017](#)). There are, however, no data to support elective cesarean delivery for HCV-infected women. Identifying HCV as women engage in prenatal care would allow for appropriate assessment of liver disease status and ideally facilitate linkage to HCV care after delivery. In addition, prenatal HCV diagnosis is a prerequisite for appropriate screening and care for the exposed children. Moreover, the cost-effectiveness of HCV screening in other clinical settings has improved with progressively lower costs of direct-acting antiviral-based treatment ([Selvapatt, 2015](#)); ([Assoumou, 2018](#)).

To enhance mothers' health and address public health concerns, universal testing of pregnant women for current HCV infection is recommended (see [Recommendations for Initial HCV Testing and Follow-Up](#)). Testing at the initiation of prenatal care is considered optimal to maximize opportunities for education, referral, and appropriate testing for the exposed infant. Early identification is key as women living with HCV and their exposed infants are at significant risk for not linking to appropriate evaluation or care. Women should be tested with an HCV-antibody test. If positive, this should be followed with testing for HCV RNA. HCV-infected pregnant women should be linked to care so that antiviral treatment can be initiated at the appropriate time (see the [HCV Testing and Linkage to Care](#) section). Infants of HCV-infected women should be tested and followed as described in the [HCV in Children](#) section.

Whom to Treat

Recommendation Regarding HCV Treatment and Pregnancy	
RECOMMENDED	RATING 
For women of reproductive age with known HCV infection, antiviral therapy is recommended before considering pregnancy, whenever practical and feasible, to reduce the risk of HCV transmission to future offspring.	I, B


Not Recommended Regarding HCV Treatment and Pregnancy

NOT RECOMMENDED	RATING 
Treatment during pregnancy is not recommended due to the lack of safety and efficacy data.	IIb, C

Women of reproductive age with HCV should be counseled about the benefit of antiviral treatment prior to pregnancy to improve the health of the mother and eliminate the low risk of mother-to-child transmission (MTCT). The safety of direct-acting antivirals (DAAs) in pregnancy is unknown, and there are no data on the effect of DAAs on male or female fertility. However, ribavirin is contraindicated in pregnancy due to its known teratogenicity. In addition, the risk for teratogenicity persists for up to 6 months after ribavirin cessation and applies to women taking ribavirin and female partners of men taking ribavirin. Women who become pregnant while on DAA therapy (with or without ribavirin) should discuss the risks versus benefits of continuing treatment with their physicians. If exposed to ribavirin, they should also have their maternal and fetal outcomes reported to the [ribavirin pregnancy registry](#) (see also, [Recommended Monitoring for Pregnancy-Related Issues Prior to and During Antiviral Therapy That Includes Ribavirin](#)).

Monitoring During Pregnancy

Recommendations for Monitoring HCV-Infected Women During Pregnancy

RECOMMENDED	RATING 
HCV RNA and routine liver function tests are recommended at initiation of prenatal care for HCV-antibody-positive pregnant women to assess the risk of mother-to-child transmission (MTCT) and degree of liver disease.	I, B
All pregnant women with HCV infection should receive prenatal and intrapartum care that is appropriate for their individual obstetric risk(s) as there is no currently known intervention to reduce MTCT.	I, B
In HCV-infected pregnant women with pruritus or jaundice, there should be a high index of suspicion for intrahepatic cholestasis of pregnancy (ICP) with subsequent assessment of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum bile acids.	I, B
HCV-infected women with cirrhosis should be counseled about the increased risk of adverse maternal and perinatal outcomes. Antenatal and perinatal care should be coordinated with a maternal-fetal medicine (ie, high-risk pregnancy) obstetrician.	I, B

Pregnancy Impact on HCV Infection

Pregnancy itself does not appear to negatively affect chronic HCV infection. In general, serum ALT levels decrease during the first and third trimesters of pregnancy and increase after delivery. HCV RNA levels rise during the first and third trimesters, reaching a peak during the third trimester, and decrease postpartum ([Conte, 2000](#)); ([Gervais, 2000](#)). These effects are likely due to the immunosuppressive effects of pregnancy. HCV-infected pregnant women have a higher incidence of intrahepatic cholestasis of pregnancy (ICP) (pooled OR 20.40 [95% CI, 9.39-44.33, I²=55%]) based on a meta-analysis of 3 studies when compared to noninfected pregnant women ([Wijarnpreecha, 2017](#)). ICP is associated with an increased rate of adverse maternal and fetal outcomes; all patients with this syndrome should be immediately referred

to a high-risk obstetrical specialist for monitoring and treatment.

HCV Infection Impact on Pregnancy and Perinatal Outcomes


Although some studies show an increased risk of adverse perinatal outcomes (eg, preterm delivery, low birth weight infants, and congenital anomalies) with maternal HCV infection, these risks are confounded by comorbid conditions, such as substance use ([Connell, 2011](#)). However, pregnant women with cirrhosis are at increased risk for poor maternal outcomes (ie, preeclampsia, cesarean section, hemorrhagic complication, and death) and neonatal outcomes (ie, preterm delivery, low birth weight, and neonatal death) ([Puljic, 2016](#)); ([Tan, 2008](#)). Women with cirrhosis should be counseled about these increased risks and care should be coordinated with specialists in maternal-fetal medicine.

Hepatitis C MTCT occurs at an overall rate of 5% to 15% ([Mast, 2005](#)); ([Ceci, 2001](#)); ([Shebl, 2009](#)); ([Jhaveri, 2015](#)), with the number that progress to chronic infection being 3% to 5%. No specific risk factor predicts transmission and no specific intervention (eg, antiviral, mode of delivery, or others) has been demonstrated to reduce transmission—except for suppression of HIV replication in women with HIV/HCV coinfection ([Checa Cabot, 2013](#)). Given the potential associated risk of MTCT, it is advisable to avoid invasive procedures (eg, fetal scalp monitors and forceps delivery).

The neuropsychiatric and systemic side effects of interferon-based agents and the pregnancy category X rating of ribavirin made studies involving these drugs to interrupt MTCT untenable for safety reasons. It is important to note that DAAs have not been studied as a way to interrupt MTCT. These drugs have not demonstrated significant toxicity in animal studies, and antiviral medication use has become the standard of care for people with HIV and hepatitis B infection. Therefore, it is realistic to think that DAAs could be used in the future to interrupt MTCT. However, with a low transmission rate, improved methods to identify mothers who are likely to transmit are needed to reduce the number needed to treat below 20 to prevent 1 transmission event. DAA therapy is not recommended during pregnancy to reduce MTCT due to the current lack of safety and efficacy data.

Postpartum Issues

Recommendations Regarding Breastfeeding and Postpartum Care for HCV-Infected Women

RECOMMENDED	RATING 
Breastfeeding is not contraindicated in women with HCV infection, except when the mother has cracked, damaged, or bleeding nipples, or in the context of HIV coinfection.	I, B
Women with HCV infection should have their HCV RNA reevaluated after delivery to assess for spontaneous clearance.	I, B

HCV and Breastfeeding

Breastfeeding is not a risk for HCV MTCT ([CDC, 1998](#)) with studies showing similar rates of maternal infection in breast-fed and bottle-fed infants ([Resti, 1998](#)). However, given the associated risks of HCV transmission with blood exposure and HIV transmission with breastfeeding, we recommend that HCV-infected women who breastfeed abstain from doing so while their nipples are cracked, damaged, or bleeding, or in the context of HIV/HCV coinfection.

Spontaneous Clearance in the Postpartum Period

HCV RNA levels can fluctuate during pregnancy and the postpartum period. The most frequently observed pattern is a steady rise in HCV RNA levels during pregnancy followed by a slight or significant drop (>3-4 log) in the postpartum period

([Lin, 2000](#)). This is most likely due to the release of tolerance in HCV-specific T lymphocyte responses that develops during pregnancy ([Honegger, 2013](#)). Spontaneous clearance of HCV can occur in the postpartum period. Previous studies with small numbers of patients demonstrated that up to 10% of postpartum women became HCV RNA undetectable ([Hattori, 2003](#)); ([Lin, 2000](#)); ([Honegger, 2013](#)). A recent study from Egypt demonstrated a 25% rate of spontaneous resolution that was strongly associated with the favorable IL28B allele ([Hashem, 2017](#)).

Given these findings, women should have their HCV RNA reevaluated after delivery. In that time, HCV RNA could become undetectable or rebound to prepregnancy levels. The possibility of spontaneous viral clearance should be considered for any woman who is being assessed for DAA treatment in the postpartum period.

Last update: May 24, 2018

Related References

Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni M-L, C. Horsburgh R, et al. [Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings](#). *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2018;66(3):376-384.

Boaz K, Fiore AE, Schrag SJ, Gonik B, Schulkin J. [Screening and counseling practices reported by obstetrician-gynecologists for patients with hepatitis C virus infection](#). *Infectious Diseases in Obstetrics and Gynecology*. 2003;11(1):39-44.

[CDC. Recommendations for prevention and control of hepatitis C virus \(HCV\) infection and HCV-related chronic disease](#). *MMWR Morb Mortal Wkly Rep*. 1998;47(RR-19):1-39.

Ceci O, Margiotta M, Mareello F, Francavilla R, Loizzi P, Francavilla A, et al. [Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study](#). *Journal of Pediatric Gastroenterology and Nutrition*. 2001;33(5):570 - 575.

Checa-Cabot CA, Stoszek SK, Quarleri J, Losso MH, Ivalo S, Peixoto MF, et al. [Mother-to-Child Transmission of Hepatitis C Virus \(HCV\) Among HIV/HCV-Coinfected Women](#). *Journal of the Pediatric Infectious Diseases Society* [Internet]. 2013;2(2):126 - 135. <https://www.ncbi.nlm.nih.gov/pubmed/26199724>

Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. [Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes](#). *Liver International: Official Journal of the International Association for the Study of the Liver*. 2011;31(8):1163 - 1170.

Conte D, Fraquelli M, Prati D, Colucci A, Minola E. [Prevalence and clinical course of chronic hepatitis C virus \(HCV\) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women](#). *Hepatology (Baltimore, Md.)*. 2000;31(3):751 - 755.

Fernandez N, Towers CV, Wolfe L, Hennessy MD, Weitz B, Porter S. [Sharing of Snorting Straws and Hepatitis C Virus Infection in Pregnant Women](#). *Obstetrics and Gynecology*. 2016;128(2):234-237.

Gervais A, Bacq Y, Bernuau J, Martinot M, Auperin A, Boyer N, et al. [Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C](#). *Journal of Hepatology*. 2000;32(2):293 - 299.

Hashem M, Jhaveri R, Saleh D'aA, Sharaf SA, El-Mougy F, El-Salam LAbd, et al.. [Spontaneous viral load decline and subsequent clearance of chronic HCV in postpartum women correlates with favorable IL28B allele](#). *Clinical Infectious Diseases*. 2017;.

Hattori Y, Orito E, Ohno T, Sugauchi F, Suzuki S, Sugiura M, et al. [Loss of hepatitis C virus RNA after parturition in female patients with chronic HCV infection](#). *Journal of Medical Virology*. 2003;71(2):205 - 211.

- Honegger JR, Kim S, Price AA, Kohout JA, McKnight KL, Prasad MR, et al. [Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses](#). *Nature Medicine*. 2013;19(11):1529 - 1533.
- Hughes BL, Page CM, Kuller JA, Kuller JA. [SMFM. Hepatitis C in pregnancy: screening, treatment, and management](#). *American Journal of Obstetrics and Gynecology* [Internet]. 2017;217(5):B2-B12. <https://www.ncbi.nlm.nih.gov/pubmed/28782502>
- Jhaveri R, Hashem M, El-Kamary SS, Saleh D'aA, Sharaf SA, El-Mougy F, et al. [Hepatitis C Virus \(HCV\) Vertical Transmission in 12-Month-Old Infants Born to HCV-Infected Women and Assessment of Maternal Risk Factors](#). *Open Forum Infectious Diseases*. 2015;2(2):ofv089.
- Koneru A, Nelson N, Hariri S, Canary L, Sanders KJ, Maxwell JF, et al. [Increased Hepatitis C Virus \(HCV\) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States and Kentucky, 2011-2014](#). *MMWR. Morbidity and mortality weekly report*. 2016;65(28):705-710.
- Kuncio DE, E. Newbern C, Fernandez-Viña MH, Herdman B, Johnson CC, Viner KM. [Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system](#). *Journal of Urban Health: Bulletin of the New York Academy of Medicine*. 2015;92(2):379-386.
- Kuncio DE, E. Newbern C, Johnson CC, Viner KM. [Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus-Infected Women](#). *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2016;62(8):980-985.
- Lin HH, Kao JH. [Hepatitis C virus load during pregnancy and puerperium](#). *BJOG: an international journal of obstetrics and gynaecology*. 2000;107(12):1503 - 1506.
- Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. [Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014](#). *Annals of Internal Medicine*. 2017;166(11):775-782.
- Mast EE, Hwang L-Y, Seto DSY, Nolte FS, Nainan OV, Wurtzel H, et al. [Risk factors for perinatal transmission of hepatitis C virus \(HCV\) and the natural history of HCV infection acquired in infancy](#). *The Journal of Infectious Diseases*. 2005;192(11):1880 - 1889.
- Prasad MR. [Hepatitis C Virus Screening in Pregnancy: Is It Time to Change Our Practice?](#). *Obstetrics and Gynecology*. 2016;128(2):229-230.
- Puljic A, Salati J, Doss A, Caughey AB. [Outcomes of pregnancies complicated by liver cirrhosis, portal hypertension, or esophageal varices](#). *The Journal of Maternal-Fetal & Neonatal Medicine: The Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians*. 2016;29(3):506 - 509.
- Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, de Martino M, et al. [Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection](#). *BMJ (Clinical research ed.)*. 1998;317(7156):437 - 441.
- Selvapatt N, Ward T, Bailey H, Bennett H, Thorne C, See L-M, et al. [Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre](#). *Journal of Hepatology*. 2015;63(4):797-804.
- Shebl FM, El-Kamary SS, Saleh D'aA, Abdel-Hamid M, Mikhail N, Allam A, et al. [Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages](#). *Journal of Medical Virology*. 2009;81(6):1024 - 1031.
- Tan J, Surti B, Saab S. [Pregnancy and cirrhosis](#). *Liver Transplantation: Official Publication of the American Association*

for the Study of Liver Diseases and the International Liver Transplantation Society. 2008;14(8):1081 - 1091.

Waruingi W, Mhanna MJ, Kumar D, Abughali N. [Hepatitis C Virus universal screening versus risk based selective screening during pregnancy](#). Journal of Neonatal-Perinatal Medicine. 2015;8(4):371-378.

Watts T, Stockman L, Martin J, Guilfoyle S, Vergeront JM. [Increased Risk for Mother-to-Infant Transmission of Hepatitis C Virus Among Medicaid Recipients - Wisconsin, 2011-2015](#). MMWR. Morbidity and mortality weekly report. 2017;66(42):1136-1139.

Wijarnpreecha K, Thongprayoon C, Sanguankeo A, Upala S, Ungprasert P, Cheungpasitporn W. [Hepatitis C infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis](#). Clinics and Research in Hepatology and Gastroenterology. 2017;41(1):39 - 45.